Erasca Allegedly Raised $258.8 Million Through a Shelf Registration Statement While Concealing Patent Infringement Risk and Improper Preclinical Comparisons for Its Lead Drug Candidate
Read more at prnewswire.comERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Barchart·07/15/2026 09:07:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.